Evidence map›Paper›PMID 31968301›Full record

ArticleDrug and alcohol dependence2020

Within-treatment frequency of use versus abstinence as a predictor of longitudinal post-treatment follow-up assessments of drug use.

Garrett M Fitzmaurice, Stuart R Lipsitz, Roger D Weiss

Open access · greenAbstract readComparative Study
In one paragraph

Article in Drug and alcohol dependence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Trial
  2. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Trial
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Garrett M FitzmauriceMcLean Hospital, 115 Mill Street, Belmont, MA 02478, United States; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States. Electronic address: fitzmaur@hsph.harvard.edu.
Stuart R LipsitzBrigham and Women's Hospital, 1620 Tremont Street, Boston, MA 02120, United States; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States.
Roger D WeissMcLean Hospital, 115 Mill Street, Belmont, MA 02478, United States; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States.
Brigham and Women's Hospital · USLemuel Shattuck Hospital · USMcLean Hospital · US

Funding

The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
Mentoring in Drug Abuse and Dual Diagnosis ResearchK24DA022288 · NIDA · MCLEAN HOSPITAL · PI WEISS, ROGER D. · 2007 to 2016
$1.8M
Reduction in frequency of drug use as a primary outcome and its relation to changes in health-related and other functional outcomes in stimulant use disorder trialsR33DA042847 · NIDA · MCLEAN HOSPITAL · PI FITZMAURICE, GARRETT M · 2019 to 2021
$1.3M
NIDA NIH HHS K24 DA022288NIDA NIH HHS R33 DA042847NIDA NIH HHS U10 DA015831
6 · The paper itself

Abstract

backgroundAbstinence is a widely-used endpoint in clinical trials of stimulant use disorders. A quantitative measure of frequency of use may be a more sensitive endpoint; however, it is important to establish that it is associated with post-treatment drug use. We examine and compare how within-treatment abstinence and frequency of use are related to two post-treatment longitudinal measures of drug use.

methodsFor each of three existing stimulant use disorder clinical trial datasets, we examined the association between within-treatment frequency of use (based on urine screens), within-treatment abstinence, and post-treatment follow-up assessments of drug use (urine screens and reported days of use). In joint analyses that simultaneously model the effects of within-treatment abstinence and frequency of use, it is possible to discern their relative importance as predictors of post-treatment drug use during the 12 months following the end of treatment.

resultsResults indicate a quantitative measure of within-treatment frequency of use was associated with longitudinal post-treatment follow-up assessments of drug use. Results from joint analyses of post-treatment follow-up drug use assessed by urine screens suggest that within-treatment frequency of use, rather than abstinence per se, is predictive of post-treatment drug use. However, results from joint analyses of self-report of days of use are equivocal.

conclusionResults lend support to the use of a quantitative measure of within-treatment drug use as an alternative to complete abstinence. They suggest that some within-treatment use that fall short of complete abstinence may potentially represent clinically important improvements given their association with post-treatment drug use.

Indexed as

AdultCocaineCocaine-Related DisordersCognitive Behavioral TherapyDisulfiramFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleOutcome Assessment, Health CarePsychotherapyPsychotherapy, PsychodynamicRandomized Controlled Trials as TopicTreatment OutcomeCocaineDisulfiramAbstinenceClinical trialEndpointUrine screen

Identifiers

PMID31968301
PMCPMC7039756
OpenAlexW2999032958

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.